Yestar Healthcare Holdings Co Ltd (2393) AI Stock Analysis

• Market Cap: HK$323.82M
• Dividend Yield: N/A
• Average Volume (3M): 6.83M
• Price to Earnings (P/E): 0.3
• Beta (1Y): 0.75
• Revenue Growth: 6.10%
• EPS Growth: -115.12%
• Country: HK
• Employees: 627
• Sector: Healthcare
• Sector Strength: 53
• Industry: Medical - Devices
• EPS (TTM): <0.01
• Shares Outstanding: 2,331,590,000
• 10 Day Avg. Volume: 2,416,750
• 30 Day Avg. Volume: 6,827,583
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 48 Neutral
• Price Target: HK$0.00 ▼(-100.00% Downside)

The overall stock score of 48 reflects significant financial challenges, including declining revenues and high leverage, which are the most impactful factors. Technical analysis indicates weak momentum, while valuation suggests potential undervaluation, though this is tempered by financial health concerns.

Yestar Healthcare Holdings Co Ltd Business Overview & Revenue Model

Company Description

Yestar Healthcare Holdings Company Limited, an investment holding company, engages in the manufacture, distribution, and sale of medical imaging products in Mainland China. It operates through two segments, Imaging Printing Products, and Medical Products and Equipment. The Imaging Printing Products segment manufactures and sells Fujifilm color photographic paper, industrial NDT X-ray films, and PWB films; and trades in imaging equipment. Its products are used in professional and minilabs; and industrial imaging applications. This segment provides NDT X-ray films under the Yes!Star brand. The Medical Products and Equipment segment manufactures and sells medical dry and wet films, and dental films; and sells medical equipment and diagnostic reagents. The company also distributes in vitro diagnostic products. In addition, it engages in the biotechnology development activities; management of supply chain activities; and provision of freight transportation services. The company was formerly known as Yestar International Holdings Company Limited and changed its name to Yestar Healthcare Holdings Company Limited in January 2017. Yestar Healthcare Holdings Company Limited was founded in 1971 and is headquartered in Shanghai, the People's Republic of China.

How the Company Makes Money

Yestar Healthcare Holdings Co Ltd generates revenue through the manufacturing and distribution of medical imaging products and in vitro diagnostic (IVD) consumables. Its revenue streams include the sale of X-ray films, imaging equipment, and IVD products to hospitals, clinics, and diagnostic laboratories. The company also engages in partnerships with leading medical equipment manufacturers to expand its product offerings and enhance its market presence. Additionally, Yestar may derive income from providing after-sales support and maintenance services for the products it distributes.

Yestar Healthcare Holdings Co Ltd Financial Statement Overview

Summary

Yestar Healthcare Holdings is facing significant financial challenges including declining revenues, deteriorating profitability, high leverage, and inconsistent cash flow generation. The financials are weak, with a notably poor balance sheet and cash flow situation.

Income Statement

Yestar Healthcare Holdings has experienced significant revenue volatility with a declining trend from 2019 to 2024. The gross profit margin has deteriorated from 25.8% in 2019 to 16.6% in 2024, indicating reduced profitability. The net profit margin has shown improvement, turning positive in 2024, but is largely due to a significant one-time gain rather than operational performance. EBIT and EBITDA margins have also decreased, reflecting operational challenges.

Balance Sheet

The company has a weak balance sheet characterized by negative stockholders' equity in recent years, indicating potential financial distress. The Debt-to-Equity ratio is not meaningful given the negative equity, suggesting high leverage. Despite a positive shift in equity in 2024, the overall financial stability remains questionable with a low equity ratio.

Cash Flow

Cash flow performance has been inconsistent, with operating cash flow declining from 2020 to 2024 and free cash flow turning negative. The operating cash flow to net income ratio is not meaningful for 2024 due to zero operating cash flow. The company has struggled to generate sustainable free cash flow, impacting its financial flexibility.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.41B	2.91B	4.29B	4.93B	4.11B
Gross Profit	399.20M	512.78M	708.71M	848.70M	806.88M
EBITDA	-51.93M	376.81M	19.13M	315.89M	-317.26M
Net Income	921.61M	-13.89M	-992.23M	3.33M	-590.49M
Balance Sheet
Total Assets	1.43B	3.43B	3.37B	4.56B	4.66B
Cash, Cash Equivalents and Short-Term Investments	151.78M	251.56M	418.15M	751.77M	687.13M
Total Debt	316.90M	1.63B	1.90B	1.79B	1.84B
Total Liabilities	921.84M	3.82B	3.71B	3.73B	3.80B
Stockholders Equity	461.60M	-457.50M	-408.87M	755.23M	757.04M
Cash Flow
Free Cash Flow	-26.45M	294.22M	-115.58M	665.55M	591.92M
Operating Cash Flow	12.72M	387.67M	-91.73M	715.22M	670.73M
Investing Cash Flow	380.42M	-89.82M	-18.72M	-47.67M	-37.21M
Financing Cash Flow	-502.63M	-234.37M	-180.86M	-654.20M	-604.74M

Yestar Healthcare Holdings Co Ltd Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.14
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2393, the sentiment is Neutral. The current price of 0.14 is below the 20-day moving average (MA) of 0.15, below the 50-day MA of 0.15, and above the 200-day MA of 0.10, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 44.24 is Neutral, neither overbought nor oversold. The STOCH value of 12.17 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:2393.

Yestar Healthcare Holdings Co Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1696	78 Outperform	HK$2.75B	14.02	5.49%	2.29%	-3.16%	-20.69%
1612	76 Outperform	HK$695.68M	7.79	14.73%	3.87%	17.93%	36.82%
1763	73 Outperform	HK$5.32B	11.60	8.59%	2.51%	13.59%	6.31%
2170	55 Neutral	HK$932.72M	―	-20.60%	―	11.43%	4.88%
Sector *	51 Neutral	$7.95B	-0.40	-42.50%	2.21%	22.29%	-1.85%
6118	50 Neutral	HK$620.22M	16.35	4.40%	―	-2.77%	―
2393	48 Neutral	HK$323.82M	0.31	-29.79%	―	6.10%	-115.12%

Yestar Healthcare Holdings Co Ltd Corporate Events

Yestar Healthcare Announces Change in Share Registrar

Yestar Healthcare Holdings Co Ltd announced a change in its Hong Kong Share Registrar and Transfer Office, effective from 14 July 2025. The new registrar will be Tricor Investor Services Limited, which will handle all applications for registration and transfer of shares from this date. This change is part of the company’s ongoing efforts to streamline its operations and improve shareholder services.

Yestar Healthcare Updates Board Nomination Committee

Yestar Healthcare Holdings Co Ltd announced a change in the composition of its Board’s Nomination Committee, with Ms. Liao Changxiang replacing Mr. Zhao Ziwei as a member, effective June 27, 2025. This change aligns with the amended Corporate Governance Code, ensuring compliance with updated regulations and maintaining a majority of independent non-executive directors on the committee.

Yestar Healthcare Announces Board Composition and Committee Roles

Yestar Healthcare Holdings Co Ltd has announced the composition of its board of directors and the roles within its four board committees. This organizational update is crucial for stakeholders as it outlines the leadership structure and governance, which can impact the company’s strategic direction and operational efficiency.

Yestar Healthcare Enhances Governance with New Nomination Committee Terms

Yestar Healthcare Holdings Co Ltd has outlined the terms of reference for its Nomination Committee, which is responsible for developing and implementing the nomination policy for the company’s board of directors. The committee, composed mainly of independent non-executive directors, will ensure compliance with the Hong Kong Stock Exchange’s listing rules, including director rotation and re-election requirements. This initiative is expected to enhance corporate governance and transparency, potentially impacting stakeholder confidence and the company’s market positioning.

Yestar Healthcare Secures Unanimous Shareholder Support at AGM

Yestar Healthcare Holdings Co Ltd announced that all proposed ordinary resolutions were passed at its annual general meeting held on 30 May 2025. The resolutions included re-electing directors, authorizing the board to fix remuneration, reappointing auditors, and granting mandates to issue and repurchase shares. The unanimous approval of these resolutions reflects strong shareholder support and positions the company for continued operational stability and strategic flexibility.